<DOC>
	<DOCNO>NCT01966302</DOCNO>
	<brief_summary>The purpose study see Lung LLC 's new experimental formulation medicine Beraprost Sodium , call Beraprost Sodium 314d Modified Release ( BPS-314d-MR ) , improve symptom pulmonary arterial hypertension ( PAH ) patient . An experimental drug one approve U.S. Food Drug Administration use general public . This research study patient pulmonary arterial hypertension ( PAH ) complete take part earlier research study receive old experimental formulation Beraprost Sodium , call Beraprost Sodium Modified Release ( BPS-MR ) . That early study do see BPS-MR could improve PAH . Patients may also take Tyvaso ( treprostinil ) , Tracleer ( bosentan ) , Letairis ( ambrisentan ) , Adcirca ( tadalafil ) and/or Viagra Revatio ( sildenafil ) treat PAH . The diagnosis PAH mean blood pressure lungs high normal . The increased blood pressure lung place strain heart . The strain cause heart pump less blood lung , cause shortness breath tiredness . The strain heart weaken heart muscle make less able pump blood , condition call heart failure . As heart failure develop , swell foot abdomen may occur .</brief_summary>
	<brief_title>Compassionate Use Beraprost Sodium 314d Modified Release Patients With Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description>According Lung LLC , review summary result contain within recent version BPS-314d-MR Investigators ' Brochure I concur , BPS-314d- MR show similar safety pharmacokinetic profile healthy volunteer BPS-MR . It also understand End Phase II meeting April year , FDA acknowledge Lung LLC 's intention continue development BPS-314d-MR conducting Phase III pivotal study PAH patient . This study , BPS-314d-MR-PAH-302 subsequently initiate past June . In opinion , base upon similarity two formulation , best interest patient transition treatment BPS-314d-MR . Lung LLC agree supply BPS-314d-MR patient .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Beraprost</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<criteria>Prior participation BeraprostMR study HarborUCLA No prior participation Beraprost study HarborUCLA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>prostacyclin</keyword>
	<keyword>oral</keyword>
</DOC>